Literature DB >> 16054539

Glucocorticosteroids in allergic inflammation: clinical benefits in allergic rhinitis, rhinosinusitis, and otitis media.

P van Cauwenberge1, H Van Hoecke, L Vandenbulcke, T Van Zele, C Bachert.   

Abstract

Allergic rhinitis, rhinosinusitis, and otitis media are among the most common health problems encountered in general practice. Although frequently trivialized, they affect the quality of life, represent a significant socioeconomic burden, and are associated with some serious complications. In addition, allergic rhinitis, rhinosinusitis, and otitis media are often considered as comorbidities. These disorders involve an inflammatory process of the respiratory mucosa of the nose, paranasal sinuses, or middle ear. Because of their well-known anti-inflammatory effects, the role of glucocorticosteroids in the management of these three disorders has been questioned, evaluated, and, in some cases, established.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054539     DOI: 10.1016/j.iac.2005.05.001

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  4 in total

Review 1.  Glucocorticosteroids in allergic inflammation: clinical benefits in otitis media with effusion.

Authors:  Ingeborg Dhooge; Katia Verbruggen; Liesbet Vandenbulcke
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

2.  Fluticasone furoate nasal spray in the treatment of allergic rhinitis.

Authors:  Pedro Giavina-Bianchi; Rosana Agondi; Rafael Stelmach; Alberto Cukier; Jorge Kalil
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

Review 3.  The Efficacy of Corticosteroids in the Treatment of Peritonsillar Abscess: A Meta-Analysis.

Authors:  Yeon Ji Lee; Yeon Min Jeong; Ho Seok Lee; Se Hwan Hwang
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-04-19       Impact factor: 3.372

Review 4.  Safety of intranasal corticosteroids in acute rhinosinusitis.

Authors:  Pascal Demoly
Journal:  Am J Otolaryngol       Date:  2008-06-16       Impact factor: 1.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.